CDLQI, Scorad and Ness: Are they Correlated?

Hon, Kam Lun; Kam, W. Y.C.; Lam, M. C.A.; Leung, Ting Fan; Ng, Pak Cheung

doi:10.1007/s11136-006-0019-7

Cited by 78 publications

(64 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of all the severity scales used in atopic dermatitis, it is the most widely validated disease-severity instrument [9]. SCORAD has been found to be valid and reliable, and it has shown excellent agreement with global assessments of disease severity [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22]. However, some studies have shown interobserver variation in scoring lichenification and extent of disease [8], [9], [10], [18], [20], [23].…”

Section: Resultsmentioning

confidence: 99%

Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality-of-Life Instruments 1985–2010

2011

View full text Add to dashboard Cite

BackgroundA number of disease-severity and quality-of-life (QoL) instruments have emerged in atopic dermatitis (AD) in the last decade.ObjectivesTo identify trends in outcomes instruments used in AD clinical trials and to provide a useful summary of the dimensions and validation studies for the most commonly used measures.MethodAll randomized control trials (RCTs) from 1985 to 2010 in the treatment of AD were examined.ResultsAmong the 791 RCTs reviewed, we identified 20 disease-severity and 14 QoL instruments. Of these outcomes instruments, few have been validated. SCORAD, EASI, IGA and SASSAD were the most commonly used disease-severity instruments and CDLQI, DFI, DLQI and IDQOL were the most frequently used QoL measures.LimitationsThe small number of RCTs using QoL scales makes identifying trends for QoL instruments difficult.ConclusionOverall, there is an increase in the use of disease-severity and QoL instruments in AD clinical trials.

show abstract

Section: Resultsmentioning

confidence: 99%

Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality-of-Life Instruments 1985–2010

2011

View full text Add to dashboard Cite

show abstract

“…These preliminary CDLQI results suggest that LS has a relatively small effect on a patient’s life quality 52 or that a LS-specific QOL tool may be needed. CDLQI correlated poorly with the mLoSSI, which measures different aspects of disease 53,54 .…”

Section: Discussionmentioning

confidence: 95%

The Localized Scleroderma Skin Severity Index and Physician Global Assessment of Disease Activity: A Work in Progress Toward Development of Localized Scleroderma Outcome Measures

Arkachaisri

Vilaiyuk²,

Li³

et al. 2009

J Rheumatol

160

180

View full text Add to dashboard Cite

Objective To develop and evaluate a Localized Scleroderma (LS) Skin Severity Index (LoSSI) and global assessments’ clinimetric property and effect on quality of life (QOL). Methods A 3-phase study was conducted. The first phase involved 15 patients with LS and 14 examiners who assessed LoSSI [surface area (SA), erythema (ER), skin thickness (ST), and new lesion/extension (N/E)] twice for inter/intrarater reliability. Patient global assessment of disease severity (PtGA-S) and Children’s Dermatology Life Quality Index (CDLQI) were collected for intrarater reliability evaluation. The second phase was aimed to develop clinical determinants for physician global assessment of disease activity (PhysGA-A) and to assess its content validity. The third phase involved 2 examiners assessing LoSSI and PhysGA-A on 27 patients. Effect of training on improving reliability/validity and sensitivity to change of the LoSSI and PhysGA-A was determined. Results Interrater reliability was excellent for ER [intraclass correlation coefficient (ICC) 0.71], ST (ICC 0.70), LoSSI (ICC 0.80), and PhysGA-A (ICC 0.90) but poor for SA (ICC 0.35); thus, LoSSI was modified to mLoSSI. Examiners’ experience did not affect the scores, but training/practice improved reliability. Intrarater reliability was excellent for ER, ST, and LoSSI (Spearman’s rho = 0.71–0.89) and moderate for SA. PtGA-S and CDLQI showed good intrarater agreement (ICC 0.63 and 0.80). mLoSSI correlated moderately with PhysGA-A and PtGA-S. Both mLoSSI and PhysGA-A were sensitive to change following therapy. Conclusion mLoSSI and PhysGA-A are reliable and valid tools for assessing LS disease severity and show high sensitivity to detect change over time. These tools are feasible for use in routine clinical practice. They should be considered for inclusion in a core set of LS outcome measures for clinical trials.

show abstract

“…Careful consideration of the scale properties should occur prior to use, including validity (content, construct, concurrent, discriminative), reliability (test-retest and internal consistency), responsiveness to change, and minimal clinically important difference. 58, 60, 67, 68 In clinical trials, the most commonly used scale is the Children’s Dermatology Life Quality Index (CDLQI), followed by the Dermatitis Family Impact (DFI), the Dermatology Life Quality Index (DLQI), and the Infant's Dermatology Life Quality Index. 43 But these scales were not generally designed for use in routine clinical practice.…”

Section: Disease Severity and Clinical Outcomes Assessmentmentioning

confidence: 99%

Guidelines of care for the management of atopic dermatitis

Eichenfield

Tom

Chamlin

et al. 2014

Journal of the American Academy of Dermatology

961

375

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a chronic, pruritic inflammatory dermatosis that affects up to 25% of children and 2–3% of adults. This guideline addresses important clinical questions that arise in AD management and care, providing updated and expanded recommendations based on the available evidence. In this first of four sections, methods for diagnosis and monitoring of disease, outcomes measures for assessment and common clinical associations that affect patients with AD are discussed. Known risk factors for the development of disease are also reviewed.

show abstract

CDLQI, Scorad and Ness: Are they Correlated?

Abstract: Quality of life, disease severity scores and laboratory atopic markers represent different domains in AD assessment. They do not necessarily correlate well with each other and all three aspects must be individually evaluated to assess the well-being of these patients.

Cited by 78 publications

References 24 publications

Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality-of-Life Instruments 1985–2010

Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality-of-Life Instruments 1985–2010

The Localized Scleroderma Skin Severity Index and Physician Global Assessment of Disease Activity: A Work in Progress Toward Development of Localized Scleroderma Outcome Measures

Guidelines of care for the management of atopic dermatitis

Contact Info

Product

Resources

About